Protocol Report on the Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) Study

Alzheimer's disease's (AD) prevalence is projected to increase as the population ages and current treatments are minimally effective. Transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light penetrates into the cerebral cortex, stimulates the mitochondrial respiratory chain,...

Full description

Saved in:
Bibliographic Details
Published in:Healthcare (Basel) 2023-07, Vol.11 (14), p.2017
Main Authors: Iosifescu, Dan V, Song, Xiaotong, Gersten, Maia B, Adib, Arwa, Cho, Yoonju, Collins, Katherine M, Yates, Kathy F, Hurtado-Puerto, Aura M, McEachern, Kayla M, Osorio, Ricardo S, Cassano, Paolo
Format: Article
Language:English
Subjects:
Adenosine triphosphate
Advertising executives
Alzheimer's disease
Alzheimer’s disease (AD)
Analysis
Animal cognition
Antioxidants
Brain research
Brain-derived neurotrophic factor
Care and treatment
cognition
Cognitive ability
Dementia
functional MRI (fMRI)
Glucose
Hypotheses
Laser therapy
Light therapy
Medical research
Medicine, Experimental
Methods
Mitochondria
neuromodulation
Nitric oxide
Oxidative stress
Pathogenesis
Phosphorus magnetic resonance spectroscopic imaging (31P-MRSI)
Phosphorylation
Proteins
Protocol
Resveratrol
transcranial photobiomodulation (t-PBM)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer's disease's (AD) prevalence is projected to increase as the population ages and current treatments are minimally effective. Transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light penetrates into the cerebral cortex, stimulates the mitochondrial respiratory chain, and increases cerebral blood flow. Preliminary data suggests t-PBM may be efficacious in improving cognition in people with early AD and amnestic mild cognitive impairment (aMCI). In this randomized, double-blind, placebo-controlled study with aMCI and early AD participants, we will test the efficacy, safety, and impact on cognition of 24 sessions of t-PBM delivered over 8 weeks. Brain mechanisms of t-PBM in this population will be explored by testing whether the baseline tau burden (measured with F-MK6240), or changes in mitochondrial function over 8 weeks (assessed with P-MRSI), moderates the changes observed in cognitive functions after t-PBM therapy. We will also use changes in the fMRI Blood-Oxygenation-Level-Dependent (BOLD) signal after a single treatment to demonstrate t-PBM-dependent increases in prefrontal cortex blood flow. This study will test whether t-PBM, a low-cost, accessible, and user-friendly intervention, has the potential to improve cognition and function in an aMCI and early AD population.
ISSN:2227-9032
2227-9032
DOI:10.3390/healthcare11142017